Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL
NCT07677878Phase 1Recruiting
- Sponsor
- Liping Dou
- Start
- Dec 2024
- Primary completion
- Nov 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of blinatumomab in B-cell acute lymphoblastic leukemia (B-ALL), sponsored by Liping Dou. Primary endpoint: Progression-Free Survival at 1 year. Started Dec 2024; status: recruiting.
02
Drugs
blinatumomab
03
Conditions
B-cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT07677878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07677878.